Complement activation in-vitro.
- Regina Michelis (2889092)
- Tamar Tadmor (6169466)
- Masad Barhoum (4676851)
- Mona Shehadeh (6169469)
- Lev Shvidel (6169472)
- Ariel Aviv (6169475)
- Galia Stemer (6169478)
- Najib Dally (6169481)
- Naomi Rahimi-Levene (4919683)
- Mona Yuklea (6169484)
- Andrei Braester (4676842)
Publication date
January 2019
DOI Publisher
Public Library of Science (PLoS)Abstract
C was activated in-vitro via the CP by aggregated IgG (A) or via the AP by Zymosan (B) and levels of sC5b-9 were determined. Basal sC5b-9 levels were subtracted. Values are given as mean with SEM. NC (white bars): n = 13; CLL with normal C5 (grey bars): n = 23; CLL with abnormal C5 (black bars): n = 16. *p = 0.002 vs. NC. (C) The correlation between sC5b-9 levels at baseline and after CP activation was analyzed in all subjects. NC (white circles): n = 13; CLL with normal C5 (grey circles): n = 23; CLL with abnormal C5 (black circles): n = 16.</p
Add to ORKG